Neovasc Inc. Reports Second Quarter 2009 Financi...(----------------------------------------...),Health

Date:8/19/2009

------------------------------------------------------------------------- DEFICIT, END OF PERIOD $(62,966,654) $(29,287,646) $(62,966,654) $(29,287,646) ------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------- BASIC AND DILUTED LOSS PER SHARE $ (0.05) $ (0.34) $ (0.14) $ (0.66) ------------------------------------------------------------------------- ------------------------------------------------------------------------- WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 27,384,365 5,560,477 22,570,658 5,560,477 WEIGHTED AVERAGE NUMBER OF FULLY DILUTED SHARES OUTSTANDING 28,215,935 5,560,477 23,406,692 5,560,477 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Neovasc Inc. (formerly Medical Ventures Corp.) Consolidated Statements of Cash Flows For the three and six months ended June 30 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Three months ended June 30 Six months ended June 30 2009 2008 2009 2008 ------------------------------------------------------------------------- OPERATING ACTIVITIES Net loss for the period $ (1,330,451) $ (1,915,673) $ (3,076,691) $ (3,657,248) Items not affecting cash Inventory write down - 94,404 - 94,404 Amortization 31,103 75,670 63,459 121,436
'/>"/>

SOURCE Neovasc Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites